All Comments by Paul Aisen
- And Then There Were Three: Donanemab Phase 3 Trial Positive
- Dare We Say Consensus Achieved: Lecanemab Slows the Disease
- In TRAILBLAZER, Plasma GFAP Falls, but NfL Continues to Rise
- Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline Results
- Drilling Down into the CMS Aduhelm Decision—A Primer
- Gantenerumab Prevention Trial in Sporadic Alzheimer's Begins
- CMS Plans to Limit Aduhelm Coverage to Clinical Trials
- On Donanemab, Plaques Plummet. Off Donanemab, They Stay Away
- Aducanumab Approved to Treat Alzheimer’s Disease
- Algorithm Bests Humans in Predicting Alzheimer’s
- Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
- New Data from Past BACE Inhibitor Trials Shed Light on Side Effects
- Aducanumab Still Needs to Prove Itself, Researchers Say
- Paper Alert: Two ApoE2s Provide “Exceptional” Protection Against AD
- ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab